Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million dollars. The announcement comes just two ...

The biotech company bought the genetic testing company for $256 million.

The bankrupt genetic-testing firm will hand over its entire data bank, including DNA samples of around 15 million people. Regeneron has said it will abide by 23andMe’s privacy policy, allowing ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

Dow Jones Top Company Headlines at 3 AM ET: Chinese Battery Giant CATL’s Shares Surge on Hong Kong Debut | Honda ... The listing comes as risk appetite has returned to global markets as trade ...

Dow Jones Top Company Headlines at 11 PM ET: Chinese EV Battery Giant CATL’s Shares Surge on Hong Kong Debut | The ... Chinese EV Battery Giant CATL's Shares Surge on Hong Kong Debut ...